Information  X 
Enter a valid email address

Veos PLC (VEO)

  Print      Mail a friend

Friday 20 October, 2000

Veos PLC

Boots Distribution Deal

Veos PLC
20 October 2000

                                                               2000-VEO-06
                                                          20 October 2000
For further information, please contact:       

Veos plc       
Peggy Czyzak-Dannenbaum, Chairman and CEO       Tel: +44 (0)20 7643 2753

City/Financial Enquiries:
David Simonson / Melanie Toyne Sewell
Merlin Financial Communications                 Tel: +44 (0)20 7606 1244

Healthcare / Technical Press Enquiries:
Jane Toner / Lizzy Griffith
BSMG Worldwide (UK)                             Tel:  +44 (0)20 7841 5555



                             VEOS PLC

           LETTER OF INTENT FROM BOOTS THE CHEMISTS FOR 
        EXCLUSIVE DISTRIBUTION OF OVES(TM) CONTRACEPTIVE CAP

Veos plc ('Veos'), the female healthcare company, is pleased to announce that
Boots The Chemists ('Boots') has signed a Letter of Intent to list the
Oves(TM) contraceptive cap as one of its products for over the counter sales
in 2001.

Boots intends to stock the Oves(TM) caps in larger stores nationwide on an
exclusive basis. In addition, details of the Oves(TM) cap will be included in
the Boots' contraception leaflet which is distributed widely by Boots' stores.


Before launching Oves(TM), Veos is running an awareness and education
programme with the medical and family planning community to ensure full
understanding and support for the Oves(TM) product. A list of all doctors and
family planning centres that have become familiar with Oves(TM) is intended to
be included on the Oves(TM) website (www.oves.com). The Company is also
planning to commence a UK-based efficacy trial, supplementing existing
efficacy data and coordinating with further efficacy trials due to take place
in France and the USA, the data from which will form part of the Company's
planned Food and Drug Administration (FDA) phase III (efficacy) trials. 

Commenting on this announcement, Peggy Czyzak-Dannenbaum, Chairman and Chief
Executive of Veos, said:

'We are delighted to have Boots - the leading pharmacy retailer in the UK - on
board to launch the Oves(TM) cap to the UK public.  We are implementing a
thorough contact programme to ensure that we have the full support of the
medical community. We are confident from the responses so far to Oves(TM),
that we are going to be launching one of the most innovative products in
female healthcare in recent times.'



Notes to Editors

1) Veos
Veos, incorporated in 1999, owns the patent and worldwide distribution rights
to the Oves(TM) product range, which currently consists of a revolutionary
female contraceptive cap, the fertility cap and additional applications in
protection against sexually transmitted diseases (STDs) and drug delivery
under development.  The Oves(TM) contraceptive cap is a discrete, disposable
and hygienic silicone device developed over the last decade using proven
female barrier contraceptive technologies.

In December 1999, the Company listed on the Alternative Investment Market and
raised £6.5 million (gross) of new capital by way of an institutional Placing.
The Ordinary shares of 10p each were placed at 71p per share, valuing the
Group at £16.2million. Williams de Broe is Nominated Advisor and Broker.


2) Boots The Chemists

Boots The Chemists is the UK's leading retailer of health and beauty products
with over 63,000 employees and over 1,400 stores ranging from small community
pharmacies to city centre department stores. As part of its healthcare
division, Boots dispenses over 70 million prescriptions each year, and employs
over 4,000 pharmacists. 



                                                                                
                                                               

a d v e r t i s e m e n t